Neurodegeneration in striatum induced by the mitochondrial toxin 3-nitropropionic acid: role of matrix metalloproteinase-9 in early blood-brain barrier disruption?

GW Kim, Y Gasche, S Grzeschik, JC Copin… - Journal of …, 2003 - Soc Neuroscience
GW Kim, Y Gasche, S Grzeschik, JC Copin, CM Maier, PH Chan
Journal of Neuroscience, 2003Soc Neuroscience
Blood-brain barrier (BBB) dysfunction is a potential mechanism involved in progressive
striatal damage induced by the mitochondrial excitotoxin, 3-nitropropionic acid (3-NP). After
activation by proteases and free radicals, matrix metalloproteinases (MMPs), particularly
MMP-9 and-2, can digest the endothelial basal lamina leading to BBB opening. Using CD-1
mice, we show that MMP-9 expression by zymography is increased in the injured striatum
compared with the contralateral striatum 2 hr after 3-NP injection [133.50±57.17 vs …
Blood-brain barrier (BBB) dysfunction is a potential mechanism involved in progressive striatal damage induced by the mitochondrial excitotoxin, 3-nitropropionic acid (3-NP). After activation by proteases and free radicals, matrix metalloproteinases (MMPs), particularly MMP-9 and -2, can digest the endothelial basal lamina leading to BBB opening. Using CD-1 mice, we show that MMP-9 expression by zymography is increased in the injured striatum compared with the contralateral striatum 2 hr after 3-NP injection [133.50 ± 57.17 vs 50.25 ± 13.56; mean ± SD of optical densities in arbitrary units (A.U.); p < 0.005] and remains elevated until 24 hr (179.33 ± 78.24 A.U.). After 4 hr, MMP-9 expression and activation are accompanied by an increase in BBB permeability. MMP inhibition attenuates BBB disruption, swelling, and lesion volume compared with vehicle-treated controls. There is a clear spatial relationship between MMP-9 expression and oxidized hydroethidine, indicating reactive oxygen species (ROS) production. Furthermore, transgenic mice that overexpress copper/zinc-superoxide dismutase (SOD1) show decreased lesion size and edema along with decreased immunoreactivity for MMP-9, compared with wild-type littermates (lesion: 38.8 ± 15.1 and 53.3 ± 10.3, respectively, p ≤ 0.05; edema: 21.8 ± 11.2 and 35.28 ± 11, respectively, p ≤ 0.05; MMP-9-positive cells: 352 ± 57 and 510 ± 45, respectively, p ≤ 0.005), whereas knock-out mice deficient in SOD1 display significantly greater swelling (48.65 ± 17; p ≤ 0.05). We conclude that early expression and activation of MMP-9 by ROS may be involved in early BBB disruption and progressive striatal damage after 3-NP treatment.
Soc Neuroscience